These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27779424)

  • 1. Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.
    Lyskjær I; Rasmussen MH; Andersen CL
    Epigenomics; 2016 Nov; 8(11):1449-1452. PubMed ID: 27779424
    [No Abstract]   [Full Text] [Related]  

  • 2. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
    Yu X; Li Z; Yu J; Chan MT; Wu WK
    Cell Prolif; 2015 Oct; 48(5):503-10. PubMed ID: 26202377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
    Chen Q; Xia HW; Ge XJ; Zhang YC; Tang QL; Bi F
    Asian Pac J Cancer Prev; 2013; 14(12):7421-6. PubMed ID: 24460313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line therapy in colorectal cancer.
    Berlin J
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):21-6. PubMed ID: 11204658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
    Ottaiano A; Nasti G; Cassata A; De Stefano A; Caraglia M; Avallone A
    Cancer Lett; 2017 Nov; 408():71-72. PubMed ID: 28844712
    [No Abstract]   [Full Text] [Related]  

  • 6. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy and colorectal cancer.
    Sumpter K; Cunningham D
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):105-11. PubMed ID: 11049041
    [No Abstract]   [Full Text] [Related]  

  • 8. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
    Kawakami H; Satoh T; Nakagawa K
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001
    [No Abstract]   [Full Text] [Related]  

  • 9. [Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer].
    Mishima H; Ikenaga M; Yasui M
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():554-8. PubMed ID: 22214022
    [No Abstract]   [Full Text] [Related]  

  • 10. MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer.
    Simmer F; Venderbosch S; Dijkstra JR; Vink-Börger EM; Faber C; Mekenkamp LJ; Koopman M; De Haan AF; Punt CJ; Nagtegaal ID
    Oncotarget; 2015 Sep; 6(26):22996-3007. PubMed ID: 26392389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New chemotherapies for colorectal cancer treatment].
    Louvet C
    Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B51-6. PubMed ID: 11449145
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
    Jensen NF; Smith DH; Nygård SB; Rømer MU; Nielsen KV; Brünner N
    Scand J Gastroenterol; 2012 Mar; 47(3):340-55. PubMed ID: 22181013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy, which drugs and when.
    Koopman M; Punt CJ
    Eur J Cancer; 2009 Sep; 45 Suppl 1():50-6. PubMed ID: 19775604
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs and Apoptosis in Colorectal Cancer.
    Wang H
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32731413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [mRNA quantification. The next challenge in routine diagnostics].
    Jung A; Jaitner S; Schäffauer AJ; Kirchner T
    Pathologe; 2010 Oct; 31 Suppl 2():280-4. PubMed ID: 20824431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
    Holen KD; Saltz LB
    Lancet Oncol; 2001 May; 2(5):290-7. PubMed ID: 11905784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells.
    Rasmussen MH; Lyskjær I; Jersie-Christensen RR; Tarpgaard LS; Primdal-Bengtson B; Nielsen MM; Pedersen JS; Hansen TP; Hansen F; Olsen JV; Pfeiffer P; Ørntoft TF; Andersen CL
    Nat Commun; 2016 Aug; 7():12436. PubMed ID: 27526785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
    Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
    Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.